Adding glycated albumin to HbA1c may improve glycemic monitoring and risk stratification in patients with chronic kidney disease (CKD) according to research presented at the American Society of Nephrology’s Kidney Week 2023 meeting. The study measured baseline serum glycated albumin levels in 3110 CKD patients and found that higher levels were associated with increased risks of end-stage kidney disease, cardiovascular events, and all-cause mortality. Adding glycated albumin to HbA1c provided additional prognostic information in predicting outcomes. The researchers suggest that glycated albumin may be a better glycemic index than HbA1c in CKD patients, and future trials should investigate whether targeting more normal glycated albumin levels improves patient outcomes.
Source link
Glycated Albumin Improves Prediction of Adverse CKD Outcomes
